Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Children may be eligible for this study if they:~* Are HIV-positive.~* Are between 3 months and 16 years old (consent of parent or legal guardian required). (These age requirements reflect a change.)~* Have a plasma viral load of at least 400 copies/ml at screening.~* Agree to practice abstinence or use effective methods of birth control during the study.~* Are able to take oral medication and comply with study requirements.~* Are taking at least 1 nucleoside reverse transcriptase inhibitor (NRTI), such as zidovudine (ZDV) or stavudine (d4T). Patients can begin taking NRTIs at the beginning of the study.~Exclusion Criteria~Children will not be eligible for this study if they:~* Have had more than 2 episodes of moderate to severe diarrhea or vomiting lasting more than 4 days within 3 months prior to study entry.~* Are allergic to EFZ or NFV.~* Have any disease, including hepatitis, cancer, or an active opportunistic (HIV-associated) infection.~* Are pregnant or breast-feeding.~* Are taking any other experimental drugs or certain medications.~* Have ever taken protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).